Main Interview _________________________________________________________________________________________________
studied. A recent example is the FUSE study, a randomized FDA trial in patients undergoing three-level cervical fusion. It compared standard three-level ACDF with combined anterior-posterior approach( ACDF plus a tissue-sparing posterior procedure, called CCF). The results were striking:
■ At 12 months, about 64 % of the combinedapproach patients achieved fusion, versus 19 % with ACDF alone with more than a threefold difference.
■ At 24 months, fewer than 2 % of combined-approach patients needed revision surgery, compared with 28 % of those treated with ACDF alone.
■ Complications were lower with the combined approach, and hospital stays were similar despite slightly longer operating time.
Procedure-related adverse events were significantly lower in the CCF group, and hospital length of stay remained similar despite a modest increase in operating time. A single trial does not answer every question about cervical fusion, and, like any industry-sponsored study, its findings should be interpreted carefully, considering the funding source, study design, and the need for independent confirmation. However, it provides high-quality, peer-reviewed evidence by directly comparing a new treatment with the long-standing standard of care and following both radiographic and clinical outcomes over two years.
Clinical data’ s wider impact
The influence of clinical trials extends well beyond the operating room. Regulatory agencies rely on robust clinical evidence when evaluating new medical devices. Professional medical societies use published evidence to develop treatment guidelines that help physicians make informed decisions. Hospitals and healthcare networks increasingly consider comparative effectiveness data, rather than familiarity or cost alone, when making procurement decisions. Insurance providers and government healthcare programs use clinical evidence when setting reimbursement policy. A growing emphasis on evidencebased medicine helps ensure that innovations are adopted because they improve patient care, not simply because they introduce new technology. The future of spinal fusion will be shaped not only by advances in implants and surgical techniques but by the strength of the evidence supporting them. Every welldesigned clinical trial helps identify safer, more effective ways to improve patient outcomes and reduce the need for future revision surgeries. High-quality studies such as FUSE have an impact that extends well beyond the operating room, informing clinical practice guidelines, influencing insurance coverage and government reimbursement policies, and accelerating the adoption of evidencebased innovations. By generating high-quality Level I evidence, clinical trials help transform promising surgical advances into proven standards of care, leading to safer and more effective patient care. ■
Matt Jenkins www. providencemt. com
Matt Jenkins, MS, BME, is the Vice President of Clinical Affairs at Providence Medical Technology, where he directs clinical development and medical evidence strategy across the company’ s spine portfolio. With over 20 years of progressive leadership experience in the medical device and combination product industries, Matt specializes in shaping enterprise clinical strategy, leading PMA and 510( k) programs, and integrating real-world evidence with regulatory and commercial objectives. His prior roles include serving as Director of Medical Affairs Operations at Roche Tissue Diagnostics( Ventana) and Senior Clinical Studies Engineer at BIOTRONIK. Matt holds a Master of Science in Biomedical Engineering from the University of Connecticut, as well as bachelor’ s degrees in Biochemistry and Economics from the University of Arizona.
12